TABLE 1.
Patient demographics, clinico‐pathological variables
| Characteristic | Value |
|---|---|
| Age at diagnosis, years | 64 ± 10 |
| Gender (female) | 13 (45) |
| BMI (kg/m2) | 28.9 (23.4–31.9) |
| ECOG | |
| 0 | 12 (43) |
| 1 | 17 (57) |
| Radiographic stage at diagnosis | |
| Resectable | 17 (59) |
| Borderline‐resectable | 12 (41) |
| CA19‐9 pre‐NAT, U/ml | 375 (60–758) |
| CA19‐9 post‐NAT, U/ml | 131 (31–440) |
| CA19‐9% change | −15% (−48% to 18%) |
| Operation performed | |
| Pancreaticoduodenectomy | 24 (83) |
| Distal pancreatectomy | 4 (14) |
| DP‐CAR | 1 (3) |
| Tumor size, cm | 3.5 (2.7–4.1) |
| T stage | |
| 1 | 5 (17) |
| 2 | 16 (55) |
| 3 | 8 (28) |
| N stage | |
| 0 | 8 (28) |
| 1 | 7 (24) |
| 2 | 14 (48) |
| pAJCC stage | |
| I | 6 (21) |
| II | 9 (31) |
| III | 14 (48) |
| Grade | |
| Moderately differentiated | 17 (69) |
| Poorly differentiated | 12 (41) |
| Lympho‐vascular invasion | 22 (76) |
| Perineural invasion | 24 (83) |
| Pathologic response | |
| None | 15 (52) |
| Mild‐moderate | 13 (45) |
| Near‐complete | 1 (4) |
| Positive margins | 14 (48) |
Data are reported as mean±standard deviation, median (interquartile range), or as raw number (percentage). BMI, body mass index, ECOG, Eastern Cooperative Oncology Group classification, NAT, neoadjuvant treatment, DP‐CAR, Distal pancreatectomy‐celiac axis resection, pAJCC, Pathologic American Joint Committee on Cancer Stage.